During the past decade, Retina Specialists of Michigan conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Specialists of Michigan" #1 sponsor was "Jaeb Center for Health Research" with 7 trials, followed by "Allergan" with 1 trials sponsored, "Ferris State University" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Paul Yates, MD, PhD" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Specialists of Michigan" #1 collaborator was "National Eye Institute (NEI)" with 6 trials as a collaborator, "National Institutes of Health (NIH)" with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Retina Specialists of Michigan" are "Diabetic Macular Edema" (4 trials), "Age-Related Macular Degeneration" (1 trials), "Full-thickness Macular Holes (MH)" (1 trials), "Geographic Atrophy" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "Retina Specialists of Michigan" in a lesser frequency.

Most popular intervention types in "Retina Specialists of Michigan" are "Drug" (8 trials), "Other" (3 trials), "Procedure" (3 trials), "Device" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "0.3 mg intravitreal ranibizumab" (1 trials), "1.25 mg intravitreal bevacizumab" (1 trials), "2-mg Intravitreous Aflibercept Injection" (1 trials), "2.0 mg intravitreal aflibercept" (1 trials) and "Abicipar Pegol" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Specialists of Michigan" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Retina Specialists of Michigan". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Retina Specialists of Michigan, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Specialists of Michigan, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".